PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
 
Curr HIV Res. 2011 September; 9(6): 446–469.
Published online 2011 September. doi:  10.2174/157016211798038597
PMCID: PMC3531820
Copyright © 2011 Bentham Science Publishers
Antiretroviral Therapy in Prevention of HIV and TB: Update on Current Research Efforts
Reuben Granich,*1 Somya Gupta,1 Amitabh B Sutha,1 Caoimhe Smyth,1 David Hoos,2 Marco Vitoria,1 Mariangela Simao,2 Catherine Hankins,2 Bernard Schwartlander,2 Renee Ridzon,3 Brigitte Bazin,4 Brian Williams,5 Ying-Ru Lo,1 Craig McClure,1 Julio Montaner,6 and Gottfried Hirnschall1, on behalf of the ART in Prevention of HIV and TB Research Writing Group §
1World Health Organization, Geneva, Switzerland;
2UNAIDS, Geneva, Switzerland;
3Bill and Melinda Gates Foundation, Seattle, United States of America;
4National Agency for Research on AIDS and Viral Hepatitis (ANRS), Paris, France;
5South African Centre for Epidemiological Modelling and Analysis, Stellenbosch, South Africa;
6British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
*Address correspondence to this author at the Antiretroviral Treatment and HIV Care, Department of HIV/AIDS, Building D, 1st Floor, Room 1005, World Health Organization, Avenue Appia 20, CH-1211, Geneva 27, Switzerland; Tel: 41 22 791 1459; Fax: 41 22 791 4834; E-mail: granichr/at/who.int
Received July 11, 2011; Revised August 14, 2011; Accepted August 18, 2011.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
There is considerable scientific evidence supporting the use of antiretroviral therapy (ART) in prevention of human immunodeficiency virus (HIV) and tuberculosis (TB) infections. The complex nature of the HIV and TB prevention responses, resource constraints, remaining questions about cost and feasibility, and the need to use a solid evidence base to make policy decisions, and the implementation challenges to translating trial data to operational settings require a well-organised and coordinated response to research in this area. To this end, we aimed to catalogue the ongoing and planned research activities that evaluate the impact of ART plus other interventions on HIV- and/or TB-related morbidity, mortality, risk behaviour, HIV incidence and transmission. Using a limited search methodology, 50 projects were identified examining ART as prevention, representing 5 regions and 52 countries with a global distribution. There are 24 randomised controlled clinical trials with at least 12 large randomised individual or community cluster trials in resource-constrained settings that are in the planning or early implementation stages. There is considerable heterogeneity between studies in terms of methodology, interventions and geographical location. While the identified studies will undoubtedly advance our understanding of the efficacy and effectiveness of ART for prevention, some key questions may remain unanswered or only partially answered. The large number and wide variety of research projects emphasise the importance of this research issue and clearly demonstrate the potential for synergies, partnerships and coordination across funding agencies.
Keywords: HAART, highly active antiretroviral therapy, HIV prevention, randomised controlled trials, research activities, tuberculosis prevention.
INTRODUCTION
Antiretroviral therapy (ART) reduces mortality and morbidity related to human immunodeficiency virus (HIV) infection. The need to provide expanded access to ART is now widely accepted, and there is a pressing demand for both increased investment and more efficient use of funding in order to achieve and sustain universal access [1]. Furthermore, the World Health Organization (WHO) estimates that less than 40% of people living with HIV know their status and there is a need for expanded access to HIV testing and counseling [2] both as a prevention measure itself and also as a gateway to other HIV services including care and treatment. Although ART has considerable potential to save lives while reducing HIV transmission [3-6], without a reduction in HIV incidence it is unlikely that we will be able to meet and sustain Universal Access targets by 2015 [2]. Indeed, in 2010 an estimated 58% of those eligible were not receiving ART. Besides individual benefits, ART has substantial potential to enhance prevention efforts because it suppresses HIV viral load, and therefore infectiousness, of persons already infected with HIV [5,7,8]. As a result, there is increasing scientific evidence supporting the use of ART in prevention of HIV and tuberculosis (TB) as part of broader combination prevention efforts [5,6,8]. The HIV Prevention Trials Network (HPTN) 052 randomized controlled trial assessing the effect of early ART initiation on HIV incidence reduction in discordant couples announced their results early when the data and safety monitoring board found a 96% reduction in HIV transmission in the arm that received ART immediately between 550-350 CD4 cells/ mm3 versus deferral of ART to < 250 cells/mm3 [9]. While the results from HPTN 052 include a significant benefit for earlier ART for reducing extrapulmonary TB, there was no benefit for pulmonary TB and the results have raised questions regarding the overall value of earlier ART for prevention of TB. Observational studies suggest that ART has been associated with up to a 92% reduction in the incidence of tuberculosis, benefiting both people living with HIV and potentially reducing TB transmission to others [10,11]. Recognising these benefits, research is increasingly focusing on answering open questions regarding feasibility and cost-related issues of integrating ART into combination prevention approaches.
The current scale of HIV prevention efforts may reduce new infections but are unlikely to achieve sustained and widespread reduction in HIV incidence, and there have been widespread calls for intensification of prevention efforts in both scale and scope [12]. Interest in and exploration of ART in prevention has increased and there have been a number of stakeholders who have contributed to building understanding and the scientific evidence base [5,6]. New public health interventions frequently require convincing evidence and considerable time before they are implemented. For example, research on male circumcision took approximately 20 years and culminated in three definitive randomised controlled trials (RCTs) showing consistent efficacy [13-15]. Still a number of high HIV-burden countries have not adopted circumcision as part of HIV prevention policy [16]. Similarly, prevention of mother-to-child transmission of HIV took years of basic science and field research before RCTs supported the use of ART to prevent transmission [17-21]. Ongoing areas of prevention research have been recently reviewed and include behavioural and biomedical approaches including HIV testing and counselling (including couples testing and counselling); ART; oral and topical microbicides; pre-exposure prophylaxis; vaccines; and how best to package together these interventions for specific populations (“combination HIV prevention”) [22-26]. Additionally, medication-assisted therapy (MAT) for the treatment of co-morbid opioid and other drug and alcohol use disorders among HIV-infected persons is another form of prevention via preventing relapse to drug use thereby improving adherence to ART and decreasing HIV RNA levels [27-30]. Although biomedical interventions are more amenable to individual observational and randomised controlled trials, effective prevention strategies are rarely implemented in isolation and WHO recommends a combined approach [26, 31]. The complex nature of the HIV prevention response, resource constraints, remaining questions about cost and feasibility, and the need to use a solid evidence base to make policy decisions, and the implementation challenges to translating trial data to operational settings require a well-organised and coordinated response to research on ART in prevention of HIV and TB.
In November of 2009, WHO convened a meeting of stakeholders including researchers, HIV program managers, civil society representatives, people living with HIV, human rights experts and ethicists, donors and bilateral agencies on the topic of ART for prevention. The meeting included over 100 experts who reviewed the evidence base for ART in prevention of HIV and TB, discussed ethical issues, and examined broad issues around the concept of ART for HIV prevention, including feasibility and acceptability, human rights and ethical implications, and research priorities [32]. In May 2011, the British Columbia Centre for Excellence in HIV/AIDS (BCCfE) with co-organizers WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the International AIDS Society, the United States (US) National Institutes of Health (NIH) and other stakeholders, hosted a meeting that focused on ART in prevention research [33]. It focused on critically reviewing research related to the secondary preventive benefit (as it relates to HIV and TB transmission) of expanding ART coverage among people living with HIV, commonly referred as “Treatment as Prevention” (TasP). Participants also discussed research priorities including a number of ongoing and planned research projects. To assist with strategic planning and future policy formulation, this article identifies and reviews selected “ART in prevention of HIV and TB” research efforts.
METHODS
We sought studies that evaluate the impact of ART plus other interventions on the HIV- and/or TB-related morbidity and mortality, risk behaviour, HIV incidence and transmission. We conducted a search on the websites of the National Library of Medicine, PubMed, NIH, HIV Prevention Trial Network (HPTN) and Clinical Trials.gov website to identify ongoing/planned research work on HIV and ART. The search strategy included the keywords “HIV and ART”, with “treatment”, “prevention”, “research”, "campaign" and “tuberculosis” alone and in combination. Out of nearly 500 studies, selected studies pertaining to evaluating the impact of ART plus other interventions on HIV- and/or TB-related morbidity and mortality, risk behaviour, HIV incidence and transmission were obtained. Community-based studies, randomised controlled trials, cohort studies and other types of studies were included. Scientific experts in this area of research, including funding agencies were contacted for information on current projects. They were asked to review the list of research projects on ART treatment in the prevention of HIV and TB to determine if the list was comprehensive and ensure all projects were relevant to the topic. The bibliographies of studies selected to be included in this article were again searched for additional references. We focused on explicit ART for prevention research studies and excluded studies that focused on other aspects of expanding ART or TB treatment (e.g. adherence, best regimens,) and published studies (e.g. HPTN 052). The following project details were extracted and summarized: focus of research, study design, principal interventions, primary outcome assessed, region, time period, agency and sponsors (if funded).
RESULTS
Summary of Studies
Our initial search yielded nearly 500 studies, of which 50 were taken forward for full review. Of the 50, 20 were from North America, 22 from Africa, 4 from Asia, 1 from Europe and 3 were multisite international studies. Of the 24 randomised control trials (individual or community cluster), 12 of the planned or ongoing studies were from resource-constrained settings. (See Table ​11 and Figs. ​11, ​22).
Table 1.
Table 1.
List of Ongoing and Planned Research Projects on Antiretroviral Therapy (ART) in Prevention of HIV and Tuberculosis (TB)
Fig. (1)
Fig. (1)
Timeline of projects on antiretroviral therapy (ART) in prevention of HIV and tuberculosis (TB). Note: Figure includes studies with an available timeline—others not listed.
  • DISCO - Discordant Couples Cohort Team
  • TasP – Treatment as Prevention
 (more ...)
Fig. (2)
Fig. (2)
Map representing countries planning or implementing antiretroviral therapy (ART) in prevention of HIV and/or tuberculosis (TB) research. Dark blue represents countries that are conducting ART in prevention of HIV and/or TB research, light blue represents (more ...)
Region: Africa
Scaling Up Treatment to Reduce Population Level Incidence of HIV/AIDS is a four-year study designed by investigators at the British Columbia Centre for Excellence in HIV/AIDS in British Columbia, Canada along with the Joint Clinical Research Centre in Uganda. This study uses a randomised step-wedge design to examine the impact of increased access to ART in Ugandan regions on incidence measured by home-based testing. Because of decreased scale-up of ART in the year 2011, this study is being re-evaluated. This study has received funding from the Canadian Institutes of Health Research.
Discordant Couples (DISCO) Cohort Team is a four-year cohort study of discordant couples in central-eastern Uganda. It is a partnership between researchers at the BC Centre for Excellence in HIV/AIDS in British Columbia, Canada and The AIDS Support Organisation (TASO) in Uganda [34]. The study follows 550 HIV-uninfected individuals who are co-habiting partners of HIV-infected individuals (i.e. serodiscordant). In 260 of the couples, the HIV-infected partner will be receiving ART, this therefore being the variable being manipulated. The control is 290 couples where the HIV-infected partner has not yet initiated ART (CD4 cell count > 250 cells/mm3, WHO stage I or II). This study has received funding from the Canadian Institutes of Health Research.
An HIV Prevention Program for Mochudi in Botswana, led by Harvard School of Public Health AIDS Initiative, will determine the feasibility and acceptability of a comprehensive program of interventions, including male circumcision, with a test-and-treat strategy [35]. HIV-positive people with a CD4 cell count above 250 cells/mm3 will be offered three-drug ART if they have acute infections and/or their viral load is greater than 50,000 RNA copies/mL, while those with a CD4 cell count below 250 cells/mm3 will be referred for ART through the public program. HIV incidence and molecular methods to elucidate transmission pathways will be used to evaluate the impact of the trial which will last for five years (2009-2013).
The Population Effects of Anti-Retroviral Therapy (PopART/HPTN-071) study is a cluster randomised trial developed by scientists based at the London School of Hygiene and Tropical Medicine and Imperial College London in the United Kingdom, with partners in South Africa (Western Cape) and Zambia [36]. The purpose of the study is to evaluate the impact of a Universal Testing and Treatment (UTT) intervention on population-level HIV incidence compared to enhanced standard of care in sub-Saharan Africa. The UTT intervention will be delivered as part of a comprehensive combination prevention package and will offer immediate treatment to all those who test positive for HIV irrespective of CD4 cell count. NIH funding has recently been confirmed.
Following a pilot study in 2010, the Africa Centre for Health and Population Studies at the University of KwaZulu-Natal (Africa Centre) [37] is starting the first phase of a cluster-randomised controlled trial, Treatment-as-prevention (TasP), in rural KwaZulu-Natal, South Africa, as part of its overall research objective to test the effectiveness of interventions in reducing HIV incidence in one of the HIV-hyperendemic rural communities in Southern Africa [38]. The trial is funded by the French National Agency for Research on AIDS and Viral Hepatitis (Agence Nationale de Recherche sur le SIDA et les hepatitis virales [ANRS]) and is conducted in collaboration with the University of Bordeaux, the Hôpitaux Universitaires de Genève, and the University of the Mediterranean Aix-Marseille II. The cluster-randomised trial will start in 2011 in four out of the total 32 clusters randomly assigned to either universal ART or standard of care. The primary outcome of the controlled trial is longitudinally-measured HIV incidence; secondary outcomes include the acceptability and feasibility of treatment as prevention, as well as the economic and social consequences.
Doctors Without Borders/Médecins Sans Frontières (MSF) is planning a pilot community-based Treatment as Prevention (TasP) project in KwaZulu-Natal, South Africa, in collaboration with the Department of Health, beginning in 2011. The program will aim to reduce HIV and TB incidence, in addition to reducing HIV- and TB-related morbidity and mortality, and to demonstrate the feasibility and acceptability of different approaches to enhanced testing, linkage to care, ART, and retention in care. Pending ethics approval, the project will offer ART for all patients with CD4 counts below 500 cells/mm3 and those with CD4 counts above 500 cells/mm3 if their viral load is greater than 100,000 RNA copies/mL. Combination prevention, including medical male circumcision, will be offered and substantial efforts will be made to reduce “leakage” across the test, link, treat, and retain cascade. HIV incidence will be measured by synthetic cohort prevalence surveys at baseline and every 2-3 years.
The Sustainable East Africa Research for Community Health (SEARCH) collaboration and University of California, San Francisco are performing pilot studies and community mapping, funded by NIH and the World Bank, in preparation for a community cluster-randomised study of 40 communities to evaluate health (HIV, TB, malaria, maternal mortality), economic and education outcomes of offering treatment to all HIV-infected persons in three East African countries—Uganda, Kenya and Tanzania. Intervention communities will receive annual HIV testing during a community health campaign, and ART will be offered to all HIV-infected children and adults through streamlined care delivery systems. Resource mobilisation in underway for a target start date of November 2012 [39].
STOP AIDS NOW! and Clinton Health Access Initiative (CHAI) have been granted Euro 8.8 million for a Treatment Centered Prevention (TCP) project in Swaziland from 2011-2014 [40]. Titled MaxART Maximizing ART for Better Health and Zero New Infections, the project will ensure that at least 90% of those in need of treatment under current guidelines are on treatment by the end of 2014. The impact of universal access to treatment based on clinical and immunologic criteria on HIV incidence will be evaluated. The study will determine whether a 50% reduction in the number of new HIV infections in Swaziland is possible by 2020.
Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis against Tuberculosis in HIV-infected Adults (ANRS 12136, TEMPRANO) study is being conducted by Université de Bordeaux [41]. This randomised trial will compare the benefits and risks of initiating ART according to the WHO guidelines to the benefits and risks of initiating ART immediately among HIV-infected adults with CD4 counts >350 cells/mm3 and <800 cells/mm3. In this study, half the patients will also receive six-month isoniazid prophylaxis. This study, to be conducted in Côte d'Ivoire from 2008 – 2013, is sponsored by ANRS.
Immunology and Outcomes after ART in HIV/TB co-infection is a prospective cohort study by University of Pennsylvania in Gaborone, Botswana [42]. This five-year (2009-2014) project received funding from NIH. It proposes to evaluate the relationship between very early virologic and immunologic responses to ART and risk of death in the first six months after ART initiation among adults with advanced HIV disease (CD4 count <100 cells/mm3) and active TB. This study will help improve the outcomes in global ART scale-up efforts.
Enhance Prevention in Couples (EPIC) is a study being conducted by ICAP at Columbia University in collaboration with Ministry of Health in Lesotho aiming to address HIV transmission among discordant couples [43]. The National Institute of Allergy and Infectious Diseases (NIAID) has financed this four-year study to conduct several feasibility/acceptability and modelling studies aiming towards a randomized clinical trial that will evaluate the effect of Enhanced Prevention Package versus Standard of Care on risk of HIV acquisition in HIV-negative partners within HIV-discordant couples in Lesotho.
Multi-component, targeted HIV Prevention for Sub-Saharan Africa: PreventionRx is a four-year study by University of Washington that started in 2010 and is receiving financing from NIH [44]. Based on epidemiologic analyses and mathematical modelling of determinants of heterosexual HIV transmission in sub-Saharan Africa and potential impact of targeted preventive interventions, this study will design an evidence-based behavioural and biomedical intervention package to be delivered through a home-based voluntary counselling and testing (VCT) to highest-risk individuals. A community-randomised effectiveness trial of this prevention package (which will include interventions like ART and male circumcision) will be implemented in Eastern and Southern Africa to determine effects of interventions on population-level HIV transmission.
Interventions to Decrease HIV Infectiousness in Uganda and South Africa is another University of Washington project being funded by NIH for the period 2010-2013 [45]. It will start in July 2011 and build on the home-based VCT platform (HBCT-plus) in high HIV prevalence areas of Uganda and KwaZulu-Natal. The aim is to increase the knowledge of HIV-positive status with behavioural change, and reduce HIV infectiousness through effective linkages to ART and treatment of co-infections. The performance of the HBCT-plus program will be measured by impact on community viral load and transmission potential.
HIV/HAART and Pregnancy/Contraception in Rakai, Uganda, a Johns Hopkins University project from 2009-2012, has received funding from NIH [46]. This study seeks to test how decisions regarding HIV prevention, contraceptive use and pregnancy desires are modified by availability and use of ART and effect of ART on pregnancy outcomes, contraceptive use and HIV risk transmission.
Impact of HIV, ART and TB Genotype on Survival in Multi-drug Resistant (MDR) TB, a 5-year study designed by Albert Einstein College of Medicine, has received funding from NIAID starting 2010 [47]. It will take place in rural South Africa and examine the impact of ART on improving survival in MDR TB/HIV co-infection. Furthermore, the study will examine the effect of MDR TB and HIV co-treatment on outcomes for each disease.
Integrated Prevention Demonstration Campaign (IPD) was an innovative public health campaign organized by Vestergaard Frandsen, Kenyan Ministry of Health and Cooperative Housing Foundation (CHF) International in the Lurambi division of western Kenya in 2008 [48]. The campaign included community-based voluntary HIV testing, counselling, on-the-spot CD4 cell count and distribution of CarePack, which contained interventions like condoms and educational material. The campaign was successful in reaching 80% of the targeted population in 7 days in an area with a very poor HIV testing rate, and mean CD4 count for HIV-positives was above 560 cells/mm3. All people who tested positive were referred for further care. Post-campaign studies are underway to determine the impact of easy access to HIV testing, disease prevention commodities and referral to care services on HIV incidence. Future integrated multi-disease prevention campaigns that include HIV, TB, malaria and other disease prevention research components are targeted for selected countries in sub-Saharan Africa.
Gender-specific Combination HIV Prevention for Youth in High-Burden Settings (MP3-Youth) is an NIH-funded study that will determine, mathematically model, and pilot evidence-based intervention prevention packages for male and female youth in western Kenya, including HIV testing and ART referrals [49]. The study is led by New York University in partnership with University of Nairobi and Impact Research and Development Organisation (IRDO), a local non-governmental organization (NGO).
The Test and Linkage to Care (TLC-IDU) Kenya study will provide data regarding implementation of the seek, test, treat and retain paradigm with injection drug users (IDUs) in sub-Saharan Africa. The team (led by Kenya’s National AIDS and Sexually Transmitted Infection [STI] Control Programme along with New York University) will conduct a cluster-randomised stepped wedge trial of Kenya’s planned needle exchange program, utilising rapid HIV and point of care CD4 testing and referral to peer ART case managers for people living with HIV with CD4 <350 cells/mm3.
IeDEA Southern Africa is a large collaborative network of 23 HIV treatment sites in Botswana, Lesotho, Malawi, Mozambique, South Africa, Zambia and Zimbabwe. The current database includes 288,015 adults (251,759 on ART) and 30,470 children (24,277 on ART). The coordination and data centres of IeDEA-South Africa are located in Bern, Switzerland and Cape Town, South Africa. This observational database is used to develop an individual-based, comprehensive mathematical model of the impact of ART on HIV transmission in Southern Africa. In particular, the role of routine viral load monitoring, the impact of the new WHO guidelines and the effect of increasing ART coverage will be explored.
Swaziland HIV Incidence Measurement Survey (SHIMS) is designed to be a four-year, population-level HIV incidence study assessing the impact of expanded HIV prevention, care, and treatment activities in Swaziland [50]. The assessment entails two serial, short-term cohorts to estimate and compare HIV incidence rates before and after a national male circumcision campaign, ART scale-up and other prevention activities. Primary outcomes include HIV incidence rates in men and women, HIV incidence rates in circumcised and uncircumcised men, and sexual risk behaviours in high-risk age groups of men and women. The SHIMS study is a joint endeavour of the Swaziland Ministry of Health, the US President’s Emergency Plan for AIDS Relief (PEPFAR) programme in Swaziland, the US Centers for Disease Control and Prevention (CDC), International Center for AIDS Care and Treatment Programs (ICAP) at Columbia University and the University of Washington.
The Zambian Ministry of Health and key partners will implement a National Antiretroviral Programme operational research project focused on the ability of ART sites to implement 2010 adult HIV treatment recommendations to treat HIV-infected adults in discordant relationships and determine patient outcomes. Over the past decade, Zambia’s National HIV Care and Treatment Programme has expanded at a rapid pace. By end of 2010, the country had more than 450 antiretroviral care and treatment facilities, 1200 prevention of mother-to-child transmission of HIV facilities nationwide, and had enrolled more than 500,000 adults and children into long-term care, of whom 344,000 had started ART. The 2010 Zambian Adult & Adolescent HIV Treatment Guidelines include among others, the recommendation to treat all HIV-infected adults in a serodiscordant relationship irrespective of their CD4 count in an attempt to reduce the spread of HIV in the community, particularly among discordant couples. It is estimated that up to 93% of new HIV infections in Zambia occur in couples in a stable cohabiting or marriage relationship [51] resulting in discordancy contributing significantly to the spread of HIV in this population. The national programme intends to monitor the implementation of this recommendation in operational research based in two rural districts. The focus will be on 1) establishing baseline data from these facilities on the number of couples being tested for HIV and what proportion are discordant; 2) using data to improve estimations regarding the proportion of new HIV infections occurring in individuals in a stable cohabiting or marriage relationship; 3) defining the linkage between counselling and testing, and enrollment into ART services and initiation of treatment for the HIV-infected person in a serodiscordant relationship; 4) evaluating the implementation of 2010 HIV treatment recommendations to treat all HIV-infected persons in a discordant relationship and its outcome at facility level; and 5) determining the HIV status of the negative partner through a defined time period for couples accepting ART for their own health as well as preventing the spread to the negative partner. The prospective, observational cohort study of adults accessing testing and counselling as well as ART services in two districts in Zambia will start in late 2011 and end in late 2012. It will use routine programmatic data from registers and electronic medical records in Chongwe and Mumbwa Districts, Zambia.
HIV Prevention Trials Network's HPTN-070, International HIV Testing, Linkage to Care and Treatment (iTLCT) study [52] is a proposed study to assess in high-prevalence African communities the feasibility of home-based HIV testing; home-based screening and diagnosis of TB in HIV-seropositive persons; strategies for linkage to care; using high plasma viral loads as a criterion for starting ART for those currently not eligible for ART based on prevailing clinical and CD4 guidelines; and estimating HIV prevalence in pregnant women aged 15-19 years attending antenatal clinics in participating communities.
Region: Asia
Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial is a project being undertaken by Johns Hopkins University in the US from the grants from NIH for the period 2010-2015 [53]. This project will intervene with injection drug users by implementing a new approach to HIV testing via drug treatment centres, promptly referring HIV-positive people to care, and retaining those individuals on ART in treatment. In addition, behavioural risk reduction interventions will be provided. Using a randomised controlled trial, effects of this seek, test, and treat strategy on ART uptake, ART adherence and treatment outcomes will be evaluated.
At the annual national AIDS meeting in February 2011, China announced efforts to implement a country-wide HIV Testing as Prevention Strategy and ART Treatment as Prevention Strategy as a part of National HIV/AIDS policy [54]. The National Center for AIDS/STD Control and Prevention (NCAIDS) in the Chinese Center for Disease Control and Prevention (China CDC) has collaborated with the British Columbia Centre for Excellence in HIV/AIDS (BCCfE) for this national programme. It is modelled on BCCfE's work in Vancouver, British Columbia. A recently closed study, supported by Chinese Ministry of Health, implemented by NCAIDS and Fudan University, using randomised community trial study design, demonstrated that counselling and condom promotion have hardly changed HIV incidence but antiretroviral treatment of HIV infected individuals has significantly reduced HIV incidence among discordant couples in Dehong, Yunnan, China [55]. Based on the combination of results from this study, recently released HPTN 052 results and previously published literature, China has decided, in May 2011, to provide ART to some 30,000 discordant couples irrespective of CD4 count as quickly as possible. Given the uncertainty of long-term benefit and risk, an ongoing evaluation of the treating discordant couple programme will be carried out, collaborating with BCCfE, WHO, UNAIDS, and US CDC’s Global AIDS Program (GAP) in China.
Also, NCAIDS and AIDS Care China will operationalise the Treatment 2.0 strategy in Wuhan City and Xiangfang City (Hubei) from 2011 onwards, and later on in two other sites in Yunnan and Guangxi with the support of WHO, UNAIDS, the Treatment Access Campaign, CHAI and the Pangaea Global AIDS Foundation. This pilot project focuses on community-based rapid HIV testing and access to quality ART for all medically eligible HIV patients, and will evaluate the impact of expanded access to ART. As a part of the Treatment 2.0 project, NCAIDS has proposed an impact and cost-effectiveness analysis research plan. One such study on cost-effectiveness of ART on serodiscordant couples will measure the effectiveness and cost-effectiveness between a group receiving ART and a non-ART group and between pre-ART and post-ART in terms of prevention of spousal transmission.
Vietnam is currently designing a Treatment 2.0 project that will help the health ministry in planning the country's HIV strategy. The project proposes to adopt a simple service delivery system at two pilot sites in the country and evaluate the cost-effectiveness of this new system. The treatment for prevention component of this project will evaluate the impact of alternate ART initiation criteria on HIV incidence, TB incidence and AIDS-related mortality. The modelling output and cost data will be useful in estimating the resources needed to control HIV/AIDS in a concentrated epidemic situation.
Region: Europe
Partners of People on ART: a New Evaluation of the Risks (PARTNER) study is a collaborative effort between Royal Free and Copenhagen HIV Programme (CHIP) and has been funded by the National Institute for Health Research, United Kingdom [56]. This study was approved in 2011 and will be carried out in 55 clinics in 14 countries in Europe. It aims to study HIV-serodiscordant partnerships that report having unprotected sex, to determine the risk of HIV transmission when the HIV-positive partner on ART has plasma viral load <50 copies/mL. Also, factors responsible for non-usage of condoms and for adoption of consistent condom use will be examined. Effectiveness of ART in reducing transmission is expected to be the strongest reason for non-usage of condoms.
Region: North America
British Columbia Centre for Excellence in HIV/AIDS (BCCfE), Vancouver, Canada has concentrated efforts on mitigating the HIV epidemic in the community. It focuses on hard-to-reach populations including aboriginal peoples, injection drug users, women, and men who have sex with men. Their intervention pilot project will focus on Vancouver and Prince George, British Columbia, and is designed to go beyond these two cities and to other groups. Research efforts are also directed towards HIV risk behaviour and outcomes of ART among injection drug users [57,58,59]. BCCfE’s AIDS Research Program has also focused work on ART regimens in Canada, US and sub-Saharan Africa. Some of their studies on ART include research on optimal timing of ART initiation, effect of ART on adult mortality, and relations between ART adherence and HIV-related mortality [60,61,62,63,64]. BCCfE's current research agenda focuses on Seek and Treat for Optimal Prevention of HIV/AIDS Initiative (STOP HIV/AIDS) - an initiative to evaluate the 'Treatment as Prevention' strategy in British Columbia. Key projects look at the impact of expanded ART access on HIV/AIDS-related morbidity, mortality, and HIV incidence, and the cost and cost-effectiveness of such strategies [65,66]. British Columbia Ministry of Health has provided major support for the BCCfE’s efforts to decrease HIV incidence in the community. Studies are ongoing and additional studies are slated for publication.
HAART Optimism, Drug Use and Risky Sexual Behaviour among MSM in British Columbia is a prospective study by Simon Fraser University for the period 2011-2016 and is financed by NIH [67]. This study examines the effect of a recently initiated population-level intervention (expanded universal and free-of-cost ART as an HIV prevention measure) on HIV risk behaviour among men who have sex with men (MSM) in British Columbia.
Effect of HAART Expansion on Community Levels of HIV Viral Load and HIV Risk Behaviours Among Men Who Have Sex with Men (MSM) in British Columbia is a Simon Fraser University project for the duration 2010-2013, being funded by Canadian Institutes of Health Research [68]. It will examine the impact of expansion of access to ART on risk behaviour among the MSM population in Greater Vancouver and on community HIV viral load as a marker of community infectivity.
San Francisco Department of Public Health, California research focuses on HIV health, treatment and prevention outcomes in San Francisco, especially among populations at risk. A community-based study titled Decreases in Community Viral Load are Accompanied by Reductions in New HIV Infections in San Francisco [69] was undertaken from 2004-2008 to determine best approaches for HIV prevention and treatment. It hypothesised and concluded that increased HIV testing and ART coverage and effectiveness were associated with decrease in community viral load and hence in new HIV infections. The department publishes data on HIV epidemiology and emerging trends of the HIV epidemic in the city. Studies on community-wide prevention programmes are ongoing to assist the department in forming sound health policies.
Project HOPE - Hospital Visit as Opportunity for Prevention and Engagement for HIV-infected Drug Users (NIH CTN 0049) is a multisite, three-arm randomised controlled trial that will compare two distinct approaches to improving outcomes among hospitalised substance-using HIV patients [70]. The study will include 800 patients at ten sites in urban centres across the US that are heavily affected by HIV, and will focus on viral suppression as the primary endpoint. In addition, the study will also determine linkage and retention in HIV primary care, linkage and retention in drug abuse treatment, and reduction in numbers of hospitalisations. Participants will be randomised to one of three groups: 1) an active patient navigator component: a strengths-based case management approach that includes motivation, physical escort to treatment, and face-to-face booster sessions; 2) a passive incentives/contingency management component to further motivate and reinforce completion of target behaviours; or 3) treatment as usual. Enrollment is pending and participants will be followed over a 12-month period.
HPTN 065: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States (TLC- Plus Study) [71] is being conducted by the HIV Prevention Trials Network (HPTN) in several communities in the US. Two communities serve as intervention communities (Washington, District of Columbia [DC] and the Bronx, New York) and four non-intervention communities (Chicago, Illinois; Houston, Texas; Miami, Florida; and Philadelphia, Pennsylvania). The purpose of the study is to evaluate the feasibility of an enhanced community-level “test, link to care, plus treat” strategy in the US [71]. The study includes the following components. Each component of the study involves an independent design but is interrelated to the other components: 1) Expanded HIV Testing component: involves social mobilisation, with targeted messaging to promote testing, and implementation of the universal offer of HIV testing in emergency departments and hospital inpatient admissions; 2) Linkage-to-Care and Viral Suppression components: involves site randomisation to test the effectiveness of a financial incentive (FI) intervention compared with the standard of care (SOC); 3) Prevention for Positives component: uses individual randomisation to compare the SOC plus a computer-delivered intervention with the SOC and; 4) Patient and Provider Survey component: administered at specific time points during the study to assess knowledge, attitudes and practices regarding early initiation of ART and the FI interventions. This study is funded by NIH and the US CDC and is being implemented in collaboration with Columbia University and local health departments. The study period is September 2010 to February 2014.
A Randomized Controlled Trial of HIV Testing and Linkage to Care, undertaken by Friends Research Institute and The Miriam Hospital-Lifespan is being conducted in community-based corrections facilities at two sites – Providence, Rhode Island and Baltimore, Maryland in the US [72]. First, a randomised controlled trial of HIV testing will study the efficacy of on-site rapid testing at a probation/parole office versus off-site referral at a community health centre or HIV testing clinic. The second study is a randomised trial wherein all individuals identified at community corrections with HIV will be offered enrollment in a one-year intervention study to examine the ability to improve linkage into HIV care. Participants will be randomised to receive one of two conditions: 1) Project Bridge (a case management-based strategy) for one year, or 2) Treatment as Usual (referral to standard level of care). Moreover, those randomised to treatment as usual will be given an opportunity to cross over to Project Bridge if they have failed to engage in treatment during the first three months. This project has been financed by NIH for the period 2010-2015.
Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care study is being conducted by University of California, Los Angeles among HIV-positive male ex-inmates who are being released from Los Angeles County Jail system [73]. The aim of this five-year NIH-funded study is to examine the individual and structural barriers to HIV care after release from jail and to utilize a randomised design to evaluate the impact of a peer-based health system navigation intervention on linkage and retention in care, ART adherence and viral load suppression.
Miriam Hospital (Brown University, Providence, Rhode Island) is working on Improving Linkage to HIV Care Following Release from Incarceration by designing and implementing a monitoring strategy to evaluate follow-up HIV care in community post-release [74]. This study will test the clinical and epidemiological utility of this strategy and identify individual, community, institutional and political factors influencing linkage to HIV medical care during the pre- and post-release periods. The project has also received NIH grants for a five-year period starting 2010.
University of North Carolina, Chapel Hill has received a five-year NIH grant for their study Randomized Control Trial of an Augmented Test, Treat, Link, and Retain Model for North Carolina and Texas Prisoners [75]. This ongoing trial compares a comprehensive multi-component intervention that spans incarceration and release, and includes motivational interviewing and a brief link coordination based on the University of Alabama’s Project Clinic Oriented New patient Navigation to Encourage Connection to Treatment (CONNECT) model with standard discharge planning for HIV-infected prisoners. The study will be conducted in North Carolina and Texas (which combined incarcerate 15% of all those in prison in the US). Participants will be about-to-be-released inmates with suppressed plasma HIV RNA levels. The primary aim is to determine the effect of the intervention on maintaining suppression of viraemia post-release via adherence to ART and engagement in ongoing HIV care. Secondary outcomes include risk behaviour following release.
Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois is being developed by University of Illinois in the US [76]. The project has received funds from NIH for five years starting in 2010. It constructs and evaluates a seek, test, treat (STT) model that begins at entrance to jail, continues through prison and extends into the community after release. STT has five components: 1) opt-out HIV testing in jail and prison, 2) transition case management for HIV-positive persons leaving jail and prison, 3) university-based telemedicine for all state prisoners living with HIV and HIV specialty care from jail-based staff, 4) incentives to visit community-based organizations following release from jail, and 5) social network HIV testing and partner notification. The study will also evaluate the overall impact of this model on community-level HIV viral load.
Seek, Test, and Treat Strategies study is led by Center for AIDS Intervention Research, Medical College of Wisconsin, US [77]. It was one of the twelve studies to receive grants from NIH for the period 2010-2015. The study will evaluate the cost and cost-effectiveness of a comprehensive and systematically coordinated network approach of HIV testing referral. This approach will test people in a state correctional facility being released to a major metropolitan area, (re)link HIV-positive people into low- or no-cost treatment and case management services, and seek to evaluate an innovative network method of HIV testing referral to utilise high-risk HIV-negatives in the correctional system to encourage other high-risk individuals in their social network to get tested.
CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC) Study is a research project being conducted by Miriam Hospital/Brown University, New York University, and George Washington University and is being supported by NIH for five years [78]. The TLC study modifies two information and communication technology-based tools, CARE and CARE+, for use among jail detainees in Rhode Island and Washington, DC. Using randomised controlled trials, this project will evaluate the effectiveness of CARE Corrections-delivered counselling to facilitate linkage to community HIV care, maintain HIV viral suppression, and decrease HIV transmission behaviours. The project will evaluate the cost-effectiveness of the CARE Corrections tools compared to standard of care services.
Finding, Testing and Treating High-risk Probationers and Parolees with HIV is a study by Research Triangle Institute to be conducted in Oakland, California [79]. It received grants from NIH in 2010 for five years. This project seeks to design and implement a community-based strategy of HIV testing and counselling for drug users on probation or parole, and assess the efficacy of Project Bridge compared with a usual care for HIV-positive patients using a randomised controlled trial. Outcomes of interest will be the proportion of eligible individuals who are identified and recruited, accept HIV testing, have not been HIV tested in the previous six months, and report recent HIV risk behaviour.
START Together: HIV Testing and Treatment in and after Jail is a five-year NIH-funded project focused on HIV prevention, testing and treatment for individuals in jails [80]. It is undertaken by National Development and Research Institutes at Rikers Island facilities in New York City. START Together has 3 components: 1) Project START (an HIV reentry program), 2) Computer Assessment and Risk-Reduction Education and 3) Peer Health Navigators. The study seeks to test whether START Together increases the proportion of inmates receiving HIV testing and the proportion of individuals with undetectable HIV viral load post-release.
The use of medication-assisted therapy (MAT) to enhance ART for soon-to-be-released HIV-infected criminal justice system (CJS) populations in Connecticut and Massachusetts is the focus of two NIH-funded grants by Yale School of Medicine researchers. The main hypothesis is that the prevention of relapse to drug and alcohol use via MAT will improve linkage to care for HIV-infected released CJS populations and will lead to greater HIV viral load suppression, thereby decreasing individual morbidity as well as decreasing transmission to the uninfected public. Both studies are five-year randomised, placebo-controlled trials of extended-release naltrexone, an opioid antagonist that is approved by the US Food and Drug Administration (FDA) for the treatment of opioid and alcohol dependency, among released HIV-infected CJS populations. The first study funded by the NIH, Alcohol Pharmacotherapies Among Released HIV+ Prisoners, is among prisoners in Connecticut transitioning to the community with alcohol use disorders and will assess HIV treatment, alcohol treatment and HIV risk behaviour outcomes. The second study is funded by NIH as one of the twelve Seek, Test, and Treat: Addressing HIV in the Criminal Justice System sites and is entitled Naltrexone for Opioid Dependent Released HIV+ Criminal Justice Populations. This study will take place in Massachusetts and Connecticut; HIV treatment, opioid treatment and HIV risk behaviour outcomes are examined among prisoners and jail detainees who are being released to the community. Outcomes from these studies will establish the efficacy, safety and tolerability of MAT as an effective, evidence-based treatment for opioid and alcohol dependence for released HIV+ CJS populations that can improve viral load suppression via preventing relapse to drug and alcohol use, thereby improving adherence to ART and HIV care.
The Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV (HHR) study will use National HIV Behavioral Surveillance System methodology to target HHR and overcome structural barriers to HIV testing and treatment. The primary goal of the proposed study is to evaluate the efficacy of a multi-level enhanced peer-driven intervention to seek, test, treat and retain HHR in New York City.
HIV, Buprenorphine, and the Criminal Justice System is a Yale University study that received grants from NIH for 2010-2015. It focuses on incarcerated, opiate-addicted individuals transitioning back to the community from prison or jail in Washington, DC. Opioid relapse in this group is associated with decreased ART adherence, ART discontinuation, loss in viral suppression within three months post-release and increased HIV risk behaviour. The efficacy of buprenorphine to improve adherence and retention in both drug abuse treatment and HIV care, and to reduce HIV transmission will be examined in a placebo-controlled randomised clinical trial.
Region: Global
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)'s Strategic Timing of Antiretroviral Treatment (START) is an international randomised trial in 37 countries to determine if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their CD4 cell count is above 500 cells/mm3 rather than waiting for it to drop to 350 cells/mm3 [81]. The study plans to enroll 4000 participants by the end of 2012 and follow them through 2015. The study, which is funded primarily by NIAID, will also examine how early ART will affect chances of developing resistance to HIV medicines, quality of life, health care utilisation and the cost of medical care.
Test & Treat to End AIDS (TTEA) is an international group of scientists, doctors and evaluation experts that is advocating for the US congress and executive branch of the US government to adequately fund, implement and evaluate several large-scale test and treat “implementation research” projects in three or more PEPFAR countries disproportionally affected by HIV/AIDS [82]. The purpose of these “implementation research” projects would be to determine the strategy’s effectiveness (in light of the HPTN 052 results) in significantly reducing and/or eliminating HIV transmission at the population level, significantly reducing long-term pandemic costs, saving lives, and providing donors an exit strategy from having to continually fund HIV. The start date of the advocacy project is between May 1, 2011 and April 30, 2012.
The Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER) study (ACTG 5274) is a randomised, open-label, phase IV strategy trial that will be conducted in Africa, Asia, South America, and the Caribbean in the 18 international AIDS Clinical Trials Group (ACTG) sites. This 96-week study will start in 2011 and be conducted in resource-limited settings with a high regional tuberculosis (TB) incidence (i.e. the TB incidence within the site’s expected catchment area) of more than 100 cases/100,000 population per year, a national ART programme, and documented high mortality rates among HIV-infected individuals (i.e. at least 5% overall at six months post-ART initiation). It includes participants from resource-limited settings who present with advanced HIV disease and no probable or confirmed TB, as defined in the current ACTG diagnosis appendix. Participants who are initiating ART will be randomised to one of two strategy arms: immediate, empiric TB treatment (public health approach) or local standard of care TB treatment (individualised approach). The primary endpoint is survival status in the two arms 24 weeks after randomisation. AIDS progression (any new WHO Stage 3 or 4 condition), virologic and CD4 cell response, HIV and TB drug resistance, and safety and tolerability of and adherence to HIV and TB drugs will be evaluated, as will the cost-effectiveness of the two strategies. Patients with probable or confirmed TB at screening will be excluded. The study is funded by the NIH and primary results are expected in 2014.
DISCUSSION
There is considerable scientific evidence supporting the use of ART in prevention of HIV and TB and a growing number of ongoing and planned research activities in this area [9,10,83]. Using a limited search methodology we found 50 projects representing 5 regions and 52 countries examining ART in prevention with a global distribution. There are 24 randomised controlled clinical trials with at least 12 large randomised individual or community cluster trials in resource-constrained settings that are in the planning and early implementation stages. Although by definition the studies focus on using ART to prevent HIV and TB, there is considerable heterogeneity between studies in terms of methodology, interventions (e.g. ART eligibility) and geographical location. Additionally, while the identified studies will undoubtedly advance our understanding of the efficacy and effectiveness of ART for prevention, some key questions may remain unanswered or only partially answered. For example, there are only a few randomised trials in resource-constrained settings looking at the issue of when to start ART and the population impact of expanded access to earlier ART. The large number and wide variety of research projects emphasise the importance of this research issue and clearly demonstrate the potential for synergies, partnerships and coordination across funding agencies.
There is considerable urgency to find effective solutions to prevent the 7000 new HIV infections that are estimated to occur each day. While many of the research studies will provide information over the near term, many of the key trials are in the early stages and will likely take at a minimum of two to four years for preliminary results to become available. The majority of community-based studies in resource-constrained settings are observational or prospective cohort design. Although data from observational studies is of considerable value, the WHO and other guidelines development processes favour randomised controlled trials (RCT) [84-86]. The 20-year time frame from early observational to RCT data before issuing recommendations for male circumcision provides a cautionary tale regarding potential delays in the research to policy process—in this case, most likely due to policy makers requiring evidence from RCTs before changing guidelines and developing policy. Many questions specific to ART in prevention of HIV and TB are amenable to a less expensive and more rapid operational research approach that uses data from current ART expansion efforts to answer relatively simple but important questions. For example, some research groups have opted to study operational questions and impact during district- or province-wide expansion of access to ART at higher than recommended levels. The rapid expansion of ART in resource-limited settings has been accompanied by an unprecedented collection of data on a wide variety of indicators. Although our search methodology did not specifically identify them, we anticipate the publication of retrospective analyses focusing on existing program and research data. The difficulty and delays inherent in implementing RCTs will likely mean that near- and medium-term policy decisions will necessarily need to rely on observational data, often from studies implementing combination prevention approaches. Reminiscent of infection control for TB [87,88], we may be faced with recommending a combination of evidence-based interventions without being able to attribute the decrease in transmission to a single intervention. Given the urgency of the situation, a blend of research methodologies that answer key questions resulting in near-, medium- and long-term evidence will likely be the most useful to policy makers, public health authorities and affected communities.
Our study had a number of limitations. While we used a standardised methodology and thorough review of listed studies, our search likely missed many planned or ongoing studies. This is particularly true for studies in the planning phase, as these sorts of efforts are often not widely publicised. Our search was done in English which may have excluded key projects in other languages. This is evident in the lack of studies from the South American region. Additionally, it was difficult to determine from brief descriptions of some studies whether they qualified as ART in prevention of HIV and TB studies and the funding amounts. We also did not include the growing list of published ART in prevention of HIV and TB studies. For example, the recently halted HPTN 052 study was not included, and we also did not include any ongoing or planned modelling research as we opted to focus on empiric studies. Bias may have been introduced through our use of experts to augment our list—as they were predominantly from wealthier and English-speaking settings. Understanding the operational aspects of providing HIV testing and counselling, HIV care including ART, and retention in care is critical, and our limited approach undoubtedly excluded important research in these critical areas. Finally, although basic and behavioural sciences have made considerable contributions to our understanding of the role of ART in prevention, with a few exceptions we did not include most of these sorts of studies in our list. Despite these limitations, our list is the first of its kind and provides considerable insights into the categories, duration, and location of ongoing and planned ART in prevention HIV and TB studies. We anticipate that it will engender further discussion and are hopeful that researchers will contact us for inclusion into future updates of this review. WHO is currently collecting research protocols and concept notes; email requests can be sent to the corresponding author to share a protocol and/or for more information.
Human rights are inviolable and expansion of HIV services should be done within a human rights framework [89]. Another area that has considerable importance but that may have been missed by our approach is research on the ethical and human rights aspects of expanding HIV services. Preliminary work exploring the programmatic costs of integrated human rights and community support interventions in South Africa has previously been presented elsewhere [90], and is included in this issue of Current HIV Research (Jones et al.). Additional research is needed to explore the potential risks and benefits of human rights and community support interventions. This will be particularly important for the benefits in terms of reaching individual and public health targets, as the potential risks are better described. While voluntary HIV testing and counselling programmes reaching millions of people have been implemented worldwide, monitoring of the quality of testing programmes including the respect afforded to human rights and consequences following testing have rarely been emphasised, and little programmatic or research data have been published. Access to high quality HIV counselling and testing is a fundamental aspect of the right to health care; however, efforts to expand HIV testing to a wide range of different populations have sometimes had serious problems, including violating individual consent and failure to provide confidentiality protections [91-96]. The possibility and consequences of these abuses and efforts to criminalise HIV affects both the research ethics of the above studies, whether community-based or in closed settings [95-97], and the success of ensuring a continuum from voluntary testing to long-term adherence to treatment (see Barr et al., this issue of Current HIV Research). Although we did not identify any ongoing or planned research on this important issue, we expect that research on the risks and benefits of expanding ART with and without specific human rights and community interventions will be forthcoming.
While it is increasingly clear that ART is both life-saving and a powerful prevention intervention, there are a number of open policy questions that remain unanswered. Key questions including when to start ART; the potential impact of ART on HIV and TB prevention, feasibility, acceptability, and cost; and how to achieve improved coverage are all being actively researched. Although a few important randomised controlled trials in resource-constrained settings are in the planning or implementation stages, it is highly likely that key policy decisions will need to be made using the available near- and medium-term observational data derived from programme data or specific research studies. Despite the multiplicity of research around the broad theme of ART in prevention of HIV and TB, the numerous and potentially divergent study outcomes and the staggered timelines may challenge the ability of normative agencies and countries to issue guidance in a timely manner. WHO and UNAIDS will continue to work with key stakeholders to map outstanding research issues, encourage collaboration among researchers and the community, and foster the coordination and rapid evaluation and incorporation of new evidence into policy.
ABBREVIATIONS
ACTG = AIDS Clinical Trials Group
AIDS = Acquired Immune Deficiency Syndrome
ANRS = Agence Nationale de Recherche sur le SIDA et les hepatites virales (National Agency for Research on AIDS and Viral Hepatitis, France)
ART = Antiretroviral Therapy
BCCfE = British Columbia Centre for Excellence in HIV/AIDS
CDC = (United States) Centers for Disease Control and Prevention
CHAI = Clinton Health Access Initiative
CHF = Cooperative Housing Foundation
CHIP = Copenhagen HIV Programme
CJS = Criminal Justice System
CONNECT = Clinic Oriented New Patient Navigation to Encourage Connection to Treatment (Model)
CTN = Clinical Trials Network
DISCO = Discordant Couples (Cohort Team)
DC = District of Columbia
EPIC = Enhance Prevention in Couples
FI = Financial Incentive
GAP = Global AIDS Program
HAART = Highly Active Antiretroviral Therapy
HBCT = Home-Based Counselling and Testing
HCV = Hepatitis C Virus
HHR = Heterosexuals at High Risk for HIV
HIV = Human Immunodeficiency Virus
HIV+ = HIV Positive
HOPE = Hospital Visit as an Opportunity for Prevention and Engagement for HIV- infected Drug Users
HPTN = HIV Prevention Trials Network
ICAP = International Center for AIDS Care and Treatment Programs
ICT = Information and Communication Tools
IDU = Injection Drug Users
INSIGHT = International Network for Strategic Initiatives in Global HIV Trials
IPD = Integrated Prevention Demonstration (Campaign)
iTLCT = International HIV Testing and Linkage to Care and Treatment (Study)
MAT = Medication-Assisted Therapy
MaxART = Maximizing ART
MDGs = Millennium Development Goals
MDR = Multi-Drug Resistant
MSF = Medecins sans Frontieres (Doctors without Borders)
MSM = Men Who Have Sex with Men
NCAIDS = National Center for AIDS/STD Control and Prevention
NIAID = United States National Institute of Allergy and Infectious Diseases
NIH = United States National Institutes of Health
PARTNER = Partners of People on ART: a New Evaluation of the Risks (Study)
PEPFAR = United States President’s Emergency Plan for AIDS Relief
PopART = Population Effects of Anti-Retroviral Therapy (Study)
RCT = Randomised Controlled Trial
REMEMBER = Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (Study)
SEARCH = Sustainable East Africa Research for Community Health
SHIMS = Swaziland HIV Incidence Measurement Survey
SOC = Standard of Care
START = Strategic Timing of Antiretroviral Treatment
STI = Sexually Transmitted Infection
STOP = Seek and Treat for Optimal Prevention of HIV/AIDS HIV/AIDS (Initiative)
STT = Seek, Test, (and) Treat
TASO = The AIDS Support Organisation (Uganda)
TasP = Treatment as Prevention
TB = Tuberculosis
TLC = Testing and Linkage to Care (or Testing, Linkage, and Care)
TTEA = Test and Treat to End AIDS
UK = United Kingdom
UNAIDS = Joint United Nations Programme on HIV/AIDS
US(A) = United States (of America)
UTT = Universal Testing and Treatment
VCT = Voluntary Counselling and Testing
WHO = World Health Organization

APPENDIX
  • Alex Welte
    South African Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA)
    University of Stellenbosch, Stellenbosch, South Africa,
    alexwelte/at/sun.ac.za
  • Alison End
    Country Manager, CHAI Swaziland
    Mbabane, Swaziland
    aend/at/clintonhealthaccess.org
  • Ann Duerr
    Fred Hutchinson Cancer Research Center
    HIV Vaccine Trials Network
    Seattle, WA, USA
    aduerr/at/hvtn.org
  • Ann Kurth
    Professor, New York University College of Nursing (NYUCN)
    Executive Director, NYUCN Global
    New York, NY, USA
    akurth/at/nyu.edu
  • Carlos del Rio
    AITRP Program Director
    Hubert Department of Global Health, Rollins School of Public Health
    Atlanta, Georgia, USA
    cdelrio/at/emory.edu
  • Christopher Gordon
    Chief, Secondary HIV Prevention and Translational Research Branch
    Associate Director for Prevention
    National Institute of Mental Health
    Rockville, MD, USA
    cgordon1/at/mail.nih.gov
  • Connie L Celum
    Professor of Global Health and Medicine, Adjunct Professor of Epidemiology
    Director, International Clinical Research Center
    Department of Global Health, University of Washington
    Seattle, WA, USA
    ccelum/at/u.washington.edu
  • Curt Beckwith
    Associate Professor of Medicine
    Alpert Medical School of Brown University/The Miriam Hospital
    Providence, RI
    CBeckwith/at/Lifespan.org
  • David W. Seal
    Professor
    Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin
    Milwaukee, WI, USA
    dseal/at/mcw.edu
  • David Wohl
    Associate Professor, Division of Infectious Diseases at the University of North Carolina
    Site Leader, AIDS Clinical Trials Unit
    The University of North Carolina
    Chapel Hill, NC, USA
    wohl/at/med.unc.edu
  • Diane V. Havlir
    University of California
    San Francisco, USA
    dhavlir/at/php.ucsf.edu
  • Edward Mills
    Associate Professor and Canada Research Chair, Global Health
    Faculty of Health Sciences
    University of Ottawa, Ottawa, Ontario, Canada
    edward.mills/at/uottawa.ca
  • Faye Malitz
    Director, Division of Science and Policy
    Health Resources and Services Administration (HRSA)
    Rockville, MD, USA
    Faye.Malitz/at/hrsa.hhs.gov
  • Gary Marks
    Division of HIV/AIDS Prevention - Surveillance and Epidemiology
    National Center for HIV, STD, and TB Prevention
    Atlanta, GA, USA
    gdm8/at/cdc.gov
  • Georgina Caswell
    Programme Officer
    Global Network of People Living with HIV (GNP+)
    Amsterdam, The Netherlands
    gcaswell/at/gnpplus.net
  • Gilles Van Cutsem
    Medical Coordinator, Medecins Sans Frontieres (MSF)
    South Africa
    gilles.van.cutsem/at/brussels.msf.org
  • Grant Colfax
    Director of HIV Prevention and Research
    San Francisco Department of Public Health
    San Francisco, CA, USA
    Grant.Colfax/at/sfdph.org
  • Irene Kuo
    Assistant Research Professor
    George Washington University
    School of Public Health and Health Services
    Department of Epidemiology and Biostatistics
    Washington, DC, USA
    sphirk/at/gwumc.edu
  • Izukanji Sikazwe
    Internal Medicine, Infectious Diseases
    Medical Technical Advisor National ARV Program
    Ministry of Health
    Lusaka, Zambia, Zambia
    isikazwe/at/umsom-ihvzambia.org
  • James D. Neaton
    Professor, Division of Biostatistics
    University of Minnesota School of Public Health
    Minneapolis, MN, USA
    neato001/at/umn.edu
  • Jonathan Mermin, Director
    Division of HIV/AIDS Prevention
    CDC; Atlanta, GA, USA
    jhm7/at/cdc.gov
  • Joseph Amon
    Director, Health and Human Rights Division
    Human Rights Watch
    New York, New York, USA
    amonj/at/hrw.org
  • Josiah Rich
    Director of the Center for Prisoner Health and Human Rights at the Miriam Hospital
    Professor of Medicine and Community Health, Brown Medical School
    Providence, RI, USA
    JRich/at/lifespan.org
  • Kevin De Cock
    Director, Center for Global Health
    Centers for Disease Control and Prevention
    Atlanta, Georgia, USA
    kmd2/at/cdc.gov
  • Lawrence J. Ouellet
    Research Professor
    Community Outreach Intervention Projects
    Division of Epidemiology and Biostatistics
    School of Public Health
    University of Illinois at Chicago
    Chicago, IL, USA
    ljo/at/uic.edu
  • Lisa Metsch
    Professor, Dept. of Epidemiology and Public Health
    University of Miami Miller School of Medicine
    Miami, Florida, USA
    lmetsch/at/med.miami.edu
  • Louise van Deth
    Director, STOP AIDS NOW!
    Amsterdam, The Netherlands
    lvandeth/at/stopaidsnow.nl
  • Lytt I. Gardner
    Epidemiologist
    Division of HIV/AIDS, Epi Branch
    Centers for Disease Control
    Atlanta GA, USA
    lig0/at/cdc.gov
  • Maria Mercedes Santoro
    University of Rome Tor Vergata, Department of Experimental Medicine and Biochemical Sciences
    Rome, Italy
    santormaria/at/gmail.com
  • Marie-Louise Newell
    Director, Africa Centre for Health and Population Studies, University of KwaZulu-Natal
    Professor of Health and Population Studies, University of KwaZulu-Natal
    Professor of Paediatric Epidemiology, Institute of Child Health, University College London
    mnewell/at/africacentre.ac.za
  • Mark Harrington
    Executive Director
    Treatment Action Group
    New York City, NY, USA
    Mark.Harrington/at/treatmentactiongroup.org
  • Michael S. Gordon
    Research Scientist
    Friends Research Institute Inc.
    Baltimore, MD, USA
    mgordon/at/friendsresearch.org
  • Moupali Das
    Director of Research, HIV Prevention Section
    San Francisco Department of Public Health
    Assistant Clinical Professor of Medicine, HIV/AIDS and Infectious Diseases, San Francisco General Hospital, UCSF
    San Francisco, California, USA
    dasm/at/php.UCSF.edu
  • Nathan Ford
    Medical co-ordinator, Medecins Sans Frontieres
    Geneva, Switzerland
    nathan.ford/at/msf.org
  • Navneet Garg
    Chief Development Officer
    Vestergaard Frandsen
    Lausanne Switzerland
    ng/at/vestergaard-frandsen.com
  • OliviaKeiser
    University of Bern
    Institute of Social and Preventive Medicine
    Finkenhubelweg, Bern
    Switzerland
    okeiser/at/ispm.unibe.ch
  • Peter Cherutich
    Head of HIV Prevention
    National AIDS/STD Control Programme (NASCOP), Ministry of Health
    Nairobi, Kenya
    pcheru2000/at/yahoo.com
  • Rachel M. Cohen
    Regional Executive Director
    Drugs for Neglected Diseases initiative (DNDi), North America
    New York, NY, USA
    rcohen/at/dndi.org
  • Redonna Chandler
    Branch Chief
    Division of Epidemiology, Services and Prevention Research (DESPR)
    National Institute on Drug Abuse, National Institutes on Health
    Bethesda, MD, USA
    rc274k/at/nih.gov
  • Richard Lester
    Assistant Clinical Professor
    University of British Columbia, Dept. of Medicine, Division of Infectious Diseases
    Vancouver, British Columbia, Canada
    rlester.id/at/gmail.com, richard.lester/at/bccdc.ca
  • Robert Sheneberger
    Assistant Professor, Institute of Human Virology
    University of Maryland School of Medicine
    Baltimore, MD, USA
    rsheneberger/at/ihv.umaryland.edu
  • Roger Tatoud
    Senior Programme Manager
    International HIV Clinical Trials Research Mgmt Office
    Imperial College
    London, UK
    r.tatoud/at/imperial.ac.uk
  • Ronald Scott Braithwaite
    Associate Professor
    Department of Medicine, New York University Langone Medical Center
    New York, NY, USA
    Scott.Braithwaite/at/nyumc.org
  • Sandra Springer
    Assistant Professor of Medicine
    Yale School of Medicine
    Department of Internal Medicine
    Section of Infectious Disease
    Yale AIDS Program
    New Haven, CT, USA
    sandra.springer/at/yale.edu
  • Sarah J. Fidler
    CSL in Communicable Diseases, Department of Medicine
    Department of Medicine
    Imperial College
    London, UK
    s.fidler/at/imperial.ac.uk
  • Sharonann Lynch
    HIV/AIDS Policy Advisor
    Access to Essential Medicines Campaign
    Médecins Sans Frontières (MSF)
    Geneva, Switzerland
    sharonann.lynch/at/msf.org
  • Shruti Mehta
    Department of Epidemiology
    615 N Wolfe Street, E6537
    Baltimore, MD 21205
    443.287.3837 (phone)
    410.955.1383 (fax)
    shmehta/at/jhsph.edu
  • Till Bärnighausen
    Senior Epidemiologist, Africa Centre for Health and Population Studies, University of KwaZulu-NatalAssistant Professor of Global Health, Department of Global Health and Population, Harvard School of Public Health
    Timothy D. Mastro
    Vice President
    FHI 360
    Durham, North Carolina, USA
    tmastro/at/fhi360.org
  • Veronica Miller
    Associate Research Professor
    The George Washington University, School of Public Health and Health Services
    Washington DC, USA
    vmiller/at/gwu.edu
  • Victor Dukay
    President
    Lundy Foundation
    300 West 11th Ave., Suite 15B
    Denver, Colorado 80204-3690, USA
    vic/at/lundyfoundation.org
  • Viviane Dias Lima
    Senior Statistician
    Epidemiology and Population Health, Clinical Programs, Drug Treatment Program
    British Columbia Centre for Excellence in HIV/AIDS
    Vancouver, BC, Canada
    vlima/at/cfenet.ubc.ca
  • Vu Minh Quan
    Assistant Professor, Department of Epidemiology,
    Johns Hopkins University Bloomberg School of Public Health
    Baltimore, MD, USA
    vquan/at/jhsph.edu
  • Wafaa El-Sadr
    Professor
    Columbia University Mailman School of Public Health
    New York, NY, USA
    wme1/at/columbia.edu
  • Warren O’Briain
    Executive Director
    Communicable Disease, Harm Reduction and Mental Health Promotion,
    BC Ministry of Health
    Warren.obriain/at/gov.bc.ca
  • William E. Cunningham
    Faculty Associate, UCLA Center for Health Policy Research
    Professor, UCLA School of Medicine
    Los Angeles, California, USA
    wcunningham/at/mednet.ucla.edu
  • Xavier Anglaret
    Senior Researcher
    Université Bordeaux
    Bordeaux, France
    xavier.anglaret/at/isped.u-bordeaux2.fr
  • Yvette Fleming
    Senior Advisor, Programme Manager MaxART in Swaziland
    STOP AIDS NOW!Keizersgracht 390, 1016 GB Amsterdam yfleming/at/stopaidsnow.nl
  • Zunyou Wu
    Director, National Center for AIDS/STD Control and Prevention
    Chinese Center for Disease Control and Prevention
    Changping District, Beijing, China
    wuzunyou/at/chinaaids.cn
Footnotes
§Alphabetised by first name—see appendix for contact information.
DISCLAIMER
The opinions and statements in this article are those of the authors and do not represent the official policy, endorsement or views of the World Health Organization or the National Institutes of Health.
CONFLICT OF INTEREST
None of the authors have conflicts of interest to declare.
REFERENCES
1. Schwartlander B, Stover J, Hallett T. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011; 377(9782 ):2031–41. [PubMed]
2. WHO. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. WHO Geneva Switzerland. 2010. [Accessed August 12, 2011]. Available at: http://whqlibdoc.who.int/publications/2010/978 9241500395_eng.pdf .
3. Fang C, Hsu H, Twu S. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190:879–85. [PubMed]
4. Das M, Chu PL, Santos GM. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE. 2010; 5(6 ):e11068. [PMC free article] [PubMed]
5. Montaner JS, Hogg R, Wood E. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006; 368(9534 ):531–6. [PubMed]
6. Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009; 373(9657 ):48–57. [PubMed]
7. Quinn TC, Wawer MJ, Sewankambo N. Viral load and heterosexual transmission of human immunodeficiency virus type 1.Rakai Project Study Group. N Engl J Med. 2000; 342(13 ):921–9. [PubMed]
8. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404. [PubMed]
9. Cohen MSCY, McCauley M, Gamble T. the HPTN 052 Study Team.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med . 2011. Jul 18, [Epub ahead of print]. http//www.nejm.org/doi/full/10.1056/NEJMoa1105243 . [PMC free article] [PubMed]
10. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009; 30(4 ):685–99 viii. [PMC free article] [PubMed]
11. Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C. The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci USA. 2005; 102(27 ):9619–24. [PubMed]
12. UNAIDS HIV Prevention Revolution. U AIDS Geneva, Switzerland 2010. Available at http://www.hivpreventioncommi ssion.com/index.php?q=node/43 . [Accessed August 11, 2011].
13. Auvert B, Sobngwi-Tambekou J, Cutler E. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009; 199(1 ):14–9. [PMC free article] [PubMed]
14. Quinn TC. Circumcision and HIV transmission. Curr Opin Infect Dis. 2007; 20(1 ):33–8. [PubMed]
15. Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med. 2008; 9(6 ):332–5. [PubMed]
16. WHO, UNAIDS. Progress in male circumcision scale-up: country implementation and research update. WHO/UNAIDS, Geneva, Switzerland 2010. Available at: www.malecircumcision.org/docum ents/MC_country_June2010.pdf . 2010. [Accessed August 12, 2011].
17. Shapiro RL, Hughes MD, Ogwu A. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 362(24 ):2282–94. [PMC free article] [PubMed]
18. Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev. (CD008440). [PubMed]
19. Safety and effectiveness of antiretroviral drugs during pregnancy delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges. Contemp Clin Trials. 32(1):74–85. [PubMed]
20. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011; 11(3 ):171–80. [PubMed]
21. Connor EM, Sperling RS, Gelber R. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173–80. [PubMed]
22. McCoy SI, Kangwende RA, Padian NS. Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. AIDS Behav. 2010;14(3 ):469–82. [PubMed]
23. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS. 2010; 24(5 ):621–35. [PubMed]
24. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011; 8(1 ):62–72. [PMC free article] [PubMed]
25. Galea JT, Kinsler JJ, Salazar X. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011; 22(5 ):256–62. [PMC free article] [PubMed]
26. Padian NS, McCoy SI, Manian S, Wilson D, Schwartlander B, Bertozzi S. Evaluation of Large-Scale Combination HIV Prevention Programs: Essential Issues. J Acquir Immune Defic Syndr. 2011. Jun 18, [Epub ahead of print] [PubMed]
27. Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. J Urban Health. 2010; 87(4 ):592–602. [PMC free article] [PubMed]
28. Batkis M. Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies. AIDS Patient Care STDs. 2010;24(1 ):15–22. [PubMed]
29. Springer SA. Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction. 2010;105(2 ):224–5. [PMC free article] [PubMed]
30. Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010;105(2):216–23. [PubMed]
31. WHO. Priority interventions HIV/AIDS prevention, treatment and care in the health sector (2010 version). WHO, Geneva, Switzerland. 2010. [Accessed August 12, 2011]. Available at: http://whqlibdoc.who.int/publ ications/2010/9789241500234_eng.pdf .
32. WHO. Consultation on Antiretroviral Treatment for Prevention of HIV Transmission - Meeting Report. 2-4 November 2009. WHO, Geneva, Switzerland. 2009. [Accessed August 12, 2011]. Available at http://www.who.int/hiv/ topics/artforprevention/Artmeetingreport.pdf .
33. International Workshop on Treatment as Prevention, 2011, Vancouver, British Columbia, Canada. Available at: http://www.c fenet.ubc.ca/node/5534 . [Accessed August 12, 2011].
34. Discordant Couples (DISCO) Cohort Team. Available at: http:// www.captnetwork.org/disco.html . [Accessed August 12, 2011].
35. An HIV Prevention Program for Mochudi, Botswana. Communitybased study. Harvard School of Public Health, Boston, USA. Available at: http://projectreporter.nih.gov/project_info_descriptio n.cfm?projectnumber=1R01AI083036-01 , http://www.labome.org /grant/r01/ai/an/hiv/an-hiv-prevention-program-for-mochudi-- botswana-7680502.html . [Accessed August 12, 2011].
36. PopART (Population Effects of ART) trial (HPTN071). Randomized controlled trial. London School of Hygiene and Tropical Medicine and Imperial College, London, UK. Available at: http://www1.imperial.ac.uk/departmentofmedicine/divisions/ infectiousdiseases/infectious_diseases/hiv_trials/hiv_prevention_technologies/popart/ [Accessed August 12, 2011].
37. Tanser F, Hosegood V, Bärnighausen T. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008; 37(5 ):956–62. [PubMed]
38. Bärnighausen T, Tanser F, Newell ML. Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses. 2009; 25(4 ):405–9. [PMC free article] [PubMed]
39. Health, Economic and Education Outcomes of Universal ART. Community randomized control trial. University of California, San Francisco, USA.
40. Stop AIDS Now! Dutch Post Lottery Dream Fund 2011. Available at: http://www.novamedia.nl/web/Press/2011-February.-2.5-millio n-Dutch-raise-270-million-for-charity.htm . [Accessed August 12, 2011].
41. Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis against Tuberculosis in HIV-infected Adults. Randomized control trial (TEMPRANO). Université Bordeaux, France. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00495651?term=ART+HIV&rank=78 . [Accessed August 12, 2011].
42. Immunology and Outcomes after HAART in HIV/TB co-infection. Cohort study. University of Pennsylvania. Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8016040&icde=8287787 . [Accessed August 12, 2011].
43. Enhance Prevention in Couples (EPIC). Randomized controlled trial. Columbia University Health Sciences Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=7860625&icde=8287802 . [ Accessed August 12, 2011].
44. Multi-component targeted HIV Prevention for Sub-Saharan Africa: PreventionRX. Randomized controlled trial. University of Washington. Available at: http://projectreporter.nih.gov/project_ info_description.cfm?aid=8077722&icde=8223602 . 2011. [Accessed August 12, 2011].
45. Interventions to Decrease HIV Infectiousness in Uganda and South Africa. Community randomized trial. University of Washington. Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8044884&icde=8223602 . [Accessed August 12, 2011].
46. HIV/HAART and Pregnancy/Contraception in Rakai, Uganda. John Hopkins University, Baltimore, USA. Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8048171&icde=8223602 . [Accessed August 12, 2011].
47. Impact of HIV, ART and TB Genotype on Survival in MDR TB. Albert Einstein College of Medicine. Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8012916&icde=8206866 . [Accessed August 12, 2011].
48. Lugada E, Millar D, Haskew J. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS ONE. 2010; 5(8 ):e12435. [PMC free article] [PubMed]
49. Gender-specific Combination HIV Prevention for Youth in High/burden Settings (MP3-Youth). New York University. Available at: http://projectreporter.nih.gov/project_info_descript ion.cfm?aid=8115703&icde=8564348 . [Accessed August 12, 2011].
50. Swaziland HIV Incidence Measurement Survey (SHIMS). Swaziland Ministry of Health. Available at: http://cumc. columbia.edu/dept/icap/wherewework/swaziland/index.html . [Accessed August 12, 2011].
51. Dunkle KL, Stephenson R, Karita E. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008; 371(9631 ):2183–91. [PubMed]
52. HIV Prevention Trials Network's HPTN-070 IHT, Linkage to Care and Treatment (iTLCT). Available at: http://www.hptn.org/ prevention_science/art.asp . [Accessed August 12, 2011].
53. Seek, Test, Treat Strategies for Vietnamese Drug Users: A Random Controlled Trial. John Hopkins University, Baltimore, USA. Available at: http://projectreporter.nih.gov/project_info_description.cfm?aid=8056406&icde=8228568 . [Accessed August 12, 2011].
54. Treatment as Prevention Strategy in China. National Center for AIDS/STD Control and Prevention (NCAIDS), China CDC and British Columbia Centre for Excellence in HIV/AIDS. Available at: http://www.cfenet.ubc.ca/news/releases/chinaimplements-bc-cfe%E2%80%99s-treatment-prevention-strategy-country%E2%80%99s-national-hivaids-pol . [ccessed August 12, 2011].
55. Wu Z. HIV prevention studies among high risk groups in China. A presentation at summary meeting of mega research projects on AIDS and Hepatitis major infectious diseases in China. Beijing. 2011. May 30,
56. Partners of people on ART: a New Evaluation of the Risks (PARTNER study). Observational study. Copenhagen HIV Programme (CHIP), Denmark and Royal Free and UC Medical School, UK. Available at: http://www.partnerstudy.eu/ [Accessed August 12, 2011].
57. Milloy MJ, Buxton J, Wood E, Li K, Montaner JS, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9:156. [PMC free article] [PubMed]
58. Wood E, Kerr T, Marshall BD. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. Br Med J. 2009;338:b1649. [PMC free article] [PubMed]
59. Krusi A, Milloy MJ, Kerr T. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther. 2010;15(5 ):789–96. [PubMed]
60. Loutfy MR, Genebat M, Moore D. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr. 2010;55(4):451–9. [PubMed]
61. Lima VD, Harrigan R, Bangsberg DR. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529–36. [PubMed]
62. Kitahata MM, Gange SJ, Abraham AG. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26. [PMC free article] [PubMed]
63. Anema A, Au-Yeung CG, Joffres M. Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther. 2011; 8:13. [PMC free article] [PubMed]
64. Lima VD, Hogg RS, Montaner JS. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS ONE. 2010; 5(6 ):e10991. [PMC free article] [PubMed]
65. Montaner JS, Lima VD, Barrios R. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia Canada a population-based study. Lancet. 2010; 376(9740 ):532–9. [PMC free article] [PubMed]
66. Johnston KM, Levy AR, Lima VD. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS. 2010; 24(12 ):1929–35. [PubMed]
67. HAART Optimism, Drug Use and Risky Sexual Behaviour among MSM in British Columbia. Simon Fraser University, USA. Available at: http://projectreporter.nih.gov/project_info_descript ion.cfm?aid=8138977&icde=8228568 . [Accessed August 12, 2011].
68. Effect of HAART Expansion on Community Levels of HIV Viral Load and HIV Risk Behaviours among MSM in British Columbia. Simon Fraser University, USA. Available at: http://www.fhs.sfu.ca/ research/activeprojects/effect-of-haart-expansion-on-community-levels-of . [Accessed August 11, 2011].
69. Das M, Chu PL, Santos GM. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE. 2010; 5(6 ):e11068. [PMC free article] [PubMed]
70. Project HOPE: Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users (CTN-0049). Available at: http://www.nida.nih.gov/ctn/ProtocolSelected.php?id=%2069 . [Accessed August 12, 2011].
71. TLC+: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States. Community-based study. Columbia University and Center for Disease Control and Prevention, USA. Available at: http://www.hptn.org/research_studies/hptn065.asp . [Accessed August 12, 2011].
72. A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care. Friends Research Institute, USA. Available at: http://www.friendsresearch.org/spotlight_on_research.htm , http://projectreporter.nih.gov/project_info_description.cfm?aid=8055730&icde=8206866 . [Accessed August 12, 2011].
73. Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care. Randomized controlled trial. University of California, Los Angeles, USA. Available at: http://www.labo me.org/grant/r01/da/effectiveness/of/effectiveness-of-peernavigation- to-link-released-hiv--jail-inmates-to-hiv-care- 8056358.html , http://projectreporter.nih.gov/project_info_description.cfm?aid=80 56358&icde=8223602 . [Accessed August 12, 2011].
75. Randomized Control Trial of an augmented test, treat, link, & retain model for North Carolina and Texas Prisoners. University of North Carolina, USA. Available at: http://projectreporter.nih.gov/ project_info_description.cfm?aid=8057688&icde=8228568 . [Accessed August 12, 2011].
76. An Integrated Jail-Prison-Community Model for Illinois. Community-based study. University of Illinois, Chicago, USA. Available at: http://projectreporter.nih.gov/project_info_ description.cfm?aid=8057664&icde=8262753 , http://www.experts.scival.com/uic/grantDetail.asp?t=ep1&id=9192437&o_id=1& . [Accessed August 12, 2011].
77. Seek, Test, and Treat Strategies. Community-based study. Center for AIDS Intervention Research, Medical College of Wisconsin, USA. Available at: http://www.mcw.edu/cair/CurrentResearchPro jects.htm , http://projectreporter.nih.gov/project_info_description.cfm?aid=8055746&icde=8262764 . [Accessed August 12, 2011].
78. CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC). Randomized controlled trial. Miriam Hospital, USA. Available at: http://projectreporter.nih.gov/project_ info_description.cfm?aid=8054015&icde=8222389 , http://www.gwumc.edu/sphhs/institutescenters/gwuhivaids/about/faculty/kuo.cfm . [Accessed August 12, 2011].
79. Finding, Testing and Treating High-risk Probationers and Parolees with HIV. Randomized controlled trial. Research Triangle Institute, North Carolina, USA. Available at: http://projectreporter. nih.gov/project_info_description.cfm?aid=8054126&icde=8262764 . [Accessed August 12, 2011].
80. START Together: HIV Testing and Treatment in and after Jail. Randomized controlled trial. National Development and Research Institutes, New York City, USA. Available at: http://project reporter.nih.gov/project_info_details.cfm?aid=8055789&icde=8262814 . [Accessed August 12, 2011].
81. START - Strategic timing of Antiretroviral treatment. University of Minnesota - Clinical and Translational Science Institute, USA. Available at: http://insight.ccbr.umn.edu/start/ [Accessed August 12, 2011].
82. Test and treat to end AIDS (TTEA). TTEA and Lundy Foundation, USA. Available at: http://ttea.info/ [Accessed August 12, 2011].
83. Treatment as Prevention (TasP). Community randomized control trial. University of Bordeaux, Hôpitaux Universitaires de Genève and Africa Centre for Health and Population Studies. Available at: http://www.africacentre.ac.za/Default.aspx?tabid=439 . [Accessed August 12, 2011].
84. WHO Guidelines Review Committee (GRC). Available at: http://www.who.int/kms/guidelines_review_committee/en/index.html . [Accessed August 12, 2011].
85. Guyatt GH, Oxman AD, Kunz R. Going from evidence to recommendations. Br Med J. 2008;336(7652):1049–51. [PMC free article] [PubMed]
86. Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med. 2011;171(1):18–22. [PubMed]
87. Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141. [PubMed]
88. WHO. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate settings and Households. WHO, Geneva, Switzerland 2009. Available at: http://whqlibdoc.who.int/publicat ions/2009/9789241598323_eng.pdf . [Accessed August 12, 2011].
89. Fee E, Parry M. Jonathan Mann HIV/AIDS, and human rights. J Public Health Policy. 2008;29(1):54–71. [PubMed]
90. Jones L, Akugizibwe P, Amon J. Costing human rights and community support interventions as a part of universal access to HIV treatment and care in a southern African setting. XVIII International AIDS Confeence Vienna, Austria. Abstract TUPE1033; XVIII International AIDS Conference; 2010 July 18-23; Vienna, Austria. Abstract TUPE1033. [PMC free article] [PubMed]
91. Human Rights Watch. Human Rights Watch. A Testing Challenge: The Experience of Lesotho's Universal HIV Counseling and Testing Campaign. Human Rights Watch, 2008. Available at: http://www.hrw.org/en/ reports/2012/11/18/testingchallenge . [Accessed August 12, 2011].
92. Larsson EC, Thorson A, Pariyo G. Opt-out HIV testing during antenatal care: experiences of pregnant women in rural Uganda. Health Policy Plan. 2011. Feb 3, [Epub ahead of print] [PubMed]
93. Angotti N, Dionne KY, Gaydosh L. An offer you can't refuse? Provider-initiated HIV testing in antenatal clinics in rural Malawi. Health Policy Plan. 2010; 26(4 ):307–15. [PMC free article] [PubMed]
94. Cohen JE, Amon JJ. Health and human rights concerns of drug user in detention in Guangxi, China. PLoS Med. 2008; 5(12 ):e234. [PMC free article] [PubMed]
95. UNAIDS. The China Stigma Index Report. UNAIDS and Partners, Geneva, Switzerland 2009. Available at: http://data.unaids. org/pub/Report/2009/20091127_stigmaindexsummaryreport_en.pdf . [Accessed August 12, 2011].
96. Burris S, Cameron E. The Case Against Criminalization of HIV Transmission. J Am Med Assoc. 2008;300(5):578–81. [PubMed]
97. Policy Research and Information Division of the National Center for AIDS/STD Control and Prevention, China CDC. HIV and AIDS Related Employment Discrimination in China. International Labour Organization (ILO) Country Office for China and Mongolia 2011. Available at: http://www.ilo.org/asia/whatwedo/publications/ lang--en/docName--WCMS_150386/index.htm . [Accessed August 12, 2011].
Articles from Bentham Open Access are provided here courtesy of
Bentham Science Publishers